Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 24 | 2023 | 1994 | 4.610 |
Why?
|
Carcinoma, Endometrioid | 11 | 2024 | 277 | 4.200 |
Why?
|
Endometrial Neoplasms | 22 | 2024 | 1359 | 4.100 |
Why?
|
Ovarian Neoplasms | 22 | 2024 | 4808 | 3.260 |
Why?
|
Uterine Neoplasms | 15 | 2023 | 1444 | 3.240 |
Why?
|
Vulvar Neoplasms | 5 | 2024 | 264 | 2.880 |
Why?
|
Adenocarcinoma, Mucinous | 9 | 2024 | 519 | 2.730 |
Why?
|
Papillomavirus Infections | 11 | 2023 | 1594 | 2.590 |
Why?
|
Adenocarcinoma | 18 | 2023 | 6306 | 2.550 |
Why?
|
Carcinoma in Situ | 7 | 2024 | 794 | 2.460 |
Why?
|
Endometrial Hyperplasia | 3 | 2024 | 98 | 2.420 |
Why?
|
Leiomyosarcoma | 7 | 2023 | 426 | 2.340 |
Why?
|
Endometrium | 6 | 2023 | 404 | 1.830 |
Why?
|
Smooth Muscle Tumor | 4 | 2023 | 63 | 1.780 |
Why?
|
Immunohistochemistry | 25 | 2024 | 11007 | 1.680 |
Why?
|
Placenta | 5 | 2024 | 1688 | 1.560 |
Why?
|
Precancerous Conditions | 3 | 2023 | 969 | 1.510 |
Why?
|
Ovarian Cysts | 2 | 2022 | 107 | 1.480 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 2 | 2022 | 112 | 1.400 |
Why?
|
Pathology, Clinical | 4 | 2022 | 367 | 1.360 |
Why?
|
Carcinoma | 9 | 2023 | 2340 | 1.260 |
Why?
|
Placenta Accreta | 2 | 2024 | 235 | 1.120 |
Why?
|
Menorrhagia | 2 | 2016 | 60 | 1.060 |
Why?
|
Matrix Attachment Region Binding Proteins | 2 | 2016 | 47 | 1.050 |
Why?
|
Hysterectomy | 9 | 2024 | 896 | 1.050 |
Why?
|
Endometriosis | 4 | 2023 | 856 | 1.040 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2023 | 2895 | 1.010 |
Why?
|
beta Catenin | 4 | 2024 | 1040 | 0.940 |
Why?
|
Adenosarcoma | 3 | 2021 | 36 | 0.940 |
Why?
|
Keratin-17 | 1 | 2024 | 27 | 0.930 |
Why?
|
Antigens, Differentiation | 3 | 2018 | 847 | 0.930 |
Why?
|
Neoplasm Staging | 21 | 2024 | 11064 | 0.900 |
Why?
|
GATA3 Transcription Factor | 1 | 2024 | 151 | 0.880 |
Why?
|
Female | 116 | 2024 | 386053 | 0.860 |
Why?
|
SOXB1 Transcription Factors | 1 | 2024 | 287 | 0.810 |
Why?
|
Placenta Previa | 1 | 2024 | 122 | 0.810 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 4 | 2019 | 932 | 0.810 |
Why?
|
Placenta Diseases | 1 | 2023 | 195 | 0.760 |
Why?
|
Vulvar Diseases | 1 | 2021 | 62 | 0.760 |
Why?
|
Endodermal Sinus Tumor | 1 | 2021 | 53 | 0.740 |
Why?
|
Myofibroma | 1 | 2021 | 45 | 0.730 |
Why?
|
Carcinoma, Verrucous | 1 | 2020 | 26 | 0.710 |
Why?
|
Sarcoma, Endometrial Stromal | 2 | 2019 | 93 | 0.710 |
Why?
|
Leiomyoma | 2 | 2023 | 663 | 0.710 |
Why?
|
Trophoblasts | 2 | 2023 | 219 | 0.690 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2021 | 218 | 0.680 |
Why?
|
Authorship | 1 | 2022 | 278 | 0.670 |
Why?
|
DNA Polymerase II | 1 | 2019 | 104 | 0.660 |
Why?
|
Myometrium | 2 | 2016 | 176 | 0.650 |
Why?
|
Neoplasm Invasiveness | 9 | 2024 | 3585 | 0.630 |
Why?
|
DNA Mismatch Repair | 3 | 2022 | 427 | 0.620 |
Why?
|
Humans | 120 | 2024 | 752341 | 0.600 |
Why?
|
Papillomaviridae | 7 | 2022 | 1102 | 0.580 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 512 | 0.580 |
Why?
|
Endometrial Stromal Tumors | 2 | 2018 | 46 | 0.580 |
Why?
|
Biopsy | 12 | 2021 | 6743 | 0.560 |
Why?
|
Chorionic Villi | 1 | 2016 | 53 | 0.560 |
Why?
|
Endometrial Ablation Techniques | 1 | 2016 | 7 | 0.560 |
Why?
|
Receptors, Estrogen | 3 | 2023 | 2181 | 0.540 |
Why?
|
Diagnosis, Differential | 12 | 2024 | 12898 | 0.540 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2018 | 484 | 0.540 |
Why?
|
Ovary | 4 | 2023 | 959 | 0.540 |
Why?
|
Receptors, Progesterone | 2 | 2023 | 1114 | 0.530 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1590 | 0.530 |
Why?
|
Breast | 4 | 2020 | 1975 | 0.530 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2019 | 1085 | 0.520 |
Why?
|
Uterus | 4 | 2024 | 648 | 0.510 |
Why?
|
Soft Tissue Neoplasms | 2 | 2022 | 1149 | 0.510 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 744 | 0.500 |
Why?
|
Carcinoma, Lobular | 2 | 2019 | 490 | 0.500 |
Why?
|
Dysmenorrhea | 1 | 2016 | 98 | 0.490 |
Why?
|
Adult | 44 | 2024 | 216913 | 0.480 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2015 | 67 | 0.470 |
Why?
|
Mutation, Missense | 1 | 2023 | 2556 | 0.470 |
Why?
|
Vulva | 3 | 2023 | 82 | 0.460 |
Why?
|
Observer Variation | 6 | 2021 | 2579 | 0.460 |
Why?
|
Middle Aged | 48 | 2024 | 217019 | 0.460 |
Why?
|
Appendiceal Neoplasms | 1 | 2016 | 155 | 0.450 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1203 | 0.450 |
Why?
|
Prognosis | 18 | 2023 | 29327 | 0.440 |
Why?
|
Specimen Handling | 3 | 2024 | 700 | 0.420 |
Why?
|
Biological Products | 1 | 2022 | 900 | 0.420 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6781 | 0.420 |
Why?
|
Biopsy, Needle | 2 | 2015 | 1632 | 0.420 |
Why?
|
Cervix Uteri | 6 | 2022 | 584 | 0.410 |
Why?
|
Aged | 36 | 2024 | 166562 | 0.410 |
Why?
|
Aged, 80 and over | 18 | 2024 | 58300 | 0.400 |
Why?
|
Mutation | 8 | 2023 | 29705 | 0.400 |
Why?
|
Breast Neoplasms | 10 | 2020 | 20843 | 0.400 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2022 | 4004 | 0.400 |
Why?
|
DNA Mutational Analysis | 4 | 2022 | 4110 | 0.390 |
Why?
|
Hemangioma | 1 | 2016 | 725 | 0.370 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 254 | 0.360 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3678 | 0.360 |
Why?
|
Predictive Value of Tests | 10 | 2021 | 15130 | 0.360 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2022 | 2095 | 0.350 |
Why?
|
Pregnancy | 9 | 2024 | 29439 | 0.350 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1970 | 0.340 |
Why?
|
Colonic Neoplasms | 1 | 2021 | 2503 | 0.330 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7399 | 0.330 |
Why?
|
Awards and Prizes | 2 | 2023 | 359 | 0.320 |
Why?
|
Progesterone | 1 | 2013 | 751 | 0.310 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2022 | 219 | 0.310 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 887 | 0.310 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2016 | 950 | 0.310 |
Why?
|
Lymph Node Excision | 5 | 2023 | 1290 | 0.310 |
Why?
|
Stromal Cells | 1 | 2013 | 1317 | 0.300 |
Why?
|
PTEN Phosphohydrolase | 2 | 2024 | 1114 | 0.300 |
Why?
|
Candidiasis | 1 | 2010 | 357 | 0.290 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2022 | 9207 | 0.290 |
Why?
|
Necrosis | 3 | 2022 | 1600 | 0.280 |
Why?
|
Transcription Factors | 3 | 2023 | 12060 | 0.280 |
Why?
|
Candida albicans | 1 | 2010 | 373 | 0.280 |
Why?
|
Intraoperative Care | 2 | 2021 | 759 | 0.270 |
Why?
|
Pelvic Neoplasms | 2 | 2022 | 248 | 0.270 |
Why?
|
Pancreatic Cyst | 1 | 2010 | 365 | 0.270 |
Why?
|
MutS Homolog 2 Protein | 2 | 2019 | 194 | 0.270 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2010 | 327 | 0.260 |
Why?
|
Cell Differentiation | 2 | 2013 | 11422 | 0.260 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2021 | 458 | 0.250 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2022 | 2495 | 0.230 |
Why?
|
PAX2 Transcription Factor | 1 | 2024 | 85 | 0.230 |
Why?
|
Retrospective Studies | 26 | 2024 | 79127 | 0.230 |
Why?
|
Frozen Sections | 2 | 2021 | 154 | 0.230 |
Why?
|
Brachytherapy | 3 | 2021 | 1241 | 0.230 |
Why?
|
World Health Organization | 2 | 2020 | 1294 | 0.230 |
Why?
|
Thrombospondins | 1 | 2024 | 194 | 0.220 |
Why?
|
Algorithms | 3 | 2019 | 13900 | 0.210 |
Why?
|
Databases, Protein | 2 | 2016 | 392 | 0.210 |
Why?
|
Proteomics | 1 | 2016 | 3750 | 0.210 |
Why?
|
Myxosarcoma | 1 | 2022 | 11 | 0.210 |
Why?
|
Canada | 4 | 2022 | 2103 | 0.210 |
Why?
|
Leiomyomatosis | 1 | 2022 | 69 | 0.210 |
Why?
|
Infarction | 1 | 2023 | 248 | 0.200 |
Why?
|
Gynecology | 3 | 2024 | 516 | 0.190 |
Why?
|
Computational Biology | 1 | 2013 | 3492 | 0.190 |
Why?
|
Pelvic Exenteration | 1 | 2021 | 21 | 0.190 |
Why?
|
Yolk Sac | 1 | 2021 | 79 | 0.190 |
Why?
|
Consensus | 2 | 2022 | 3034 | 0.190 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3502 | 0.180 |
Why?
|
Endopeptidases | 1 | 2024 | 772 | 0.180 |
Why?
|
Carcinosarcoma | 1 | 2021 | 106 | 0.180 |
Why?
|
Fibrosarcoma | 1 | 2022 | 305 | 0.180 |
Why?
|
Uterine Rupture | 1 | 2020 | 67 | 0.180 |
Why?
|
Mucin-6 | 1 | 2019 | 15 | 0.170 |
Why?
|
Receptor, erbB-2 | 2 | 2021 | 2483 | 0.170 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2021 | 720 | 0.170 |
Why?
|
Sensitivity and Specificity | 4 | 2021 | 14586 | 0.170 |
Why?
|
Young Adult | 8 | 2020 | 57629 | 0.170 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2020 | 73 | 0.170 |
Why?
|
Pathology, Surgical | 1 | 2020 | 149 | 0.170 |
Why?
|
Cell Nucleus | 3 | 2020 | 2904 | 0.160 |
Why?
|
Myofibroblasts | 1 | 2021 | 203 | 0.160 |
Why?
|
Serine Endopeptidases | 1 | 2024 | 1017 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 218 | 0.160 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2019 | 95 | 0.160 |
Why?
|
Lymphatic Metastasis | 4 | 2022 | 2924 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2023 | 3489 | 0.160 |
Why?
|
Fibroadenoma | 1 | 2018 | 41 | 0.150 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 194 | 0.150 |
Why?
|
Cicatrix | 1 | 2024 | 769 | 0.150 |
Why?
|
Phyllodes Tumor | 1 | 2018 | 53 | 0.150 |
Why?
|
Tumor Burden | 3 | 2021 | 1875 | 0.150 |
Why?
|
Nucleic Acid Hybridization | 1 | 2019 | 1303 | 0.150 |
Why?
|
Societies, Medical | 4 | 2023 | 3833 | 0.150 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 52 | 0.150 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6793 | 0.140 |
Why?
|
Chromogranins | 1 | 2017 | 162 | 0.140 |
Why?
|
Conization | 1 | 2016 | 17 | 0.140 |
Why?
|
Neprilysin | 2 | 2018 | 464 | 0.140 |
Why?
|
Physicians, Women | 1 | 2022 | 485 | 0.140 |
Why?
|
Electrosurgery | 1 | 2016 | 52 | 0.140 |
Why?
|
Keratin-20 | 1 | 2016 | 31 | 0.140 |
Why?
|
Mucin-2 | 1 | 2016 | 50 | 0.130 |
Why?
|
Disease Progression | 4 | 2019 | 13402 | 0.130 |
Why?
|
Mitotic Index | 1 | 2016 | 161 | 0.130 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2017 | 194 | 0.130 |
Why?
|
Ribonuclease III | 1 | 2017 | 280 | 0.130 |
Why?
|
Reference Standards | 1 | 2019 | 1004 | 0.130 |
Why?
|
Ontario | 1 | 2016 | 394 | 0.130 |
Why?
|
Mastectomy, Segmental | 1 | 2020 | 957 | 0.130 |
Why?
|
Risk Assessment | 6 | 2023 | 23783 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2023 | 1774 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 365 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12455 | 0.120 |
Why?
|
Cesarean Section | 1 | 2024 | 1374 | 0.120 |
Why?
|
Treatment Outcome | 6 | 2021 | 64245 | 0.120 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 341 | 0.120 |
Why?
|
Neoplasms | 2 | 2020 | 21808 | 0.120 |
Why?
|
Physicians | 2 | 2023 | 4550 | 0.120 |
Why?
|
Immediate-Early Proteins | 1 | 2017 | 449 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6501 | 0.120 |
Why?
|
DEAD-box RNA Helicases | 1 | 2017 | 382 | 0.120 |
Why?
|
Monitoring, Intraoperative | 1 | 2021 | 933 | 0.120 |
Why?
|
International Cooperation | 1 | 2020 | 1421 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2017 | 552 | 0.110 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 694 | 0.110 |
Why?
|
DNA, Viral | 1 | 2020 | 2176 | 0.110 |
Why?
|
RNA, Viral | 1 | 2022 | 2827 | 0.110 |
Why?
|
Cell Shape | 1 | 2014 | 373 | 0.110 |
Why?
|
Human papillomavirus 11 | 1 | 2013 | 14 | 0.110 |
Why?
|
Human papillomavirus 6 | 1 | 2013 | 16 | 0.110 |
Why?
|
Progesterone Congeners | 1 | 2013 | 44 | 0.110 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2013 | 94 | 0.110 |
Why?
|
Gene Dosage | 1 | 2017 | 1222 | 0.110 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 1987 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3177 | 0.110 |
Why?
|
Cell Size | 1 | 2014 | 621 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 606 | 0.100 |
Why?
|
Uterine Cervical Diseases | 1 | 2013 | 74 | 0.100 |
Why?
|
Adenoma | 1 | 2023 | 2141 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1387 | 0.100 |
Why?
|
In Situ Hybridization | 1 | 2016 | 1896 | 0.100 |
Why?
|
Metaplasia | 1 | 2013 | 319 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2021 | 19894 | 0.100 |
Why?
|
Lymphocytosis | 1 | 2012 | 120 | 0.100 |
Why?
|
Mesenteric Artery, Superior | 1 | 2011 | 94 | 0.100 |
Why?
|
Hemorrhage | 1 | 2023 | 3568 | 0.100 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4274 | 0.100 |
Why?
|
Hemangioendothelioma | 1 | 2011 | 111 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2020 | 2789 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2023 | 3600 | 0.090 |
Why?
|
Stomach Neoplasms | 1 | 2021 | 1398 | 0.090 |
Why?
|
Microfilament Proteins | 1 | 2016 | 1133 | 0.090 |
Why?
|
Mitosis | 1 | 2016 | 1192 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2635 | 0.090 |
Why?
|
Hemangiosarcoma | 1 | 2012 | 218 | 0.090 |
Why?
|
Nephrectomy | 2 | 2012 | 1000 | 0.090 |
Why?
|
Cystadenoma, Serous | 1 | 2010 | 101 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3321 | 0.090 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 382 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2019 | 1873 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2020 | 4717 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2017 | 21841 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2322 | 0.080 |
Why?
|
Phenotype | 3 | 2017 | 16439 | 0.080 |
Why?
|
Portal Vein | 1 | 2011 | 427 | 0.080 |
Why?
|
Time Factors | 3 | 2017 | 39854 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2016 | 1527 | 0.080 |
Why?
|
Kidney Glomerulus | 1 | 2011 | 564 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2017 | 2007 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 587 | 0.080 |
Why?
|
Premenopause | 1 | 2013 | 1034 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1828 | 0.080 |
Why?
|
Intestinal Perforation | 1 | 2010 | 252 | 0.070 |
Why?
|
Peritonitis | 1 | 2010 | 366 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 3325 | 0.070 |
Why?
|
Genital Neoplasms, Female | 1 | 2012 | 525 | 0.070 |
Why?
|
Public Health | 1 | 2020 | 2644 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2015 | 1616 | 0.070 |
Why?
|
Membrane Proteins | 1 | 2024 | 7808 | 0.070 |
Why?
|
Epithelial Cells | 2 | 2020 | 3669 | 0.070 |
Why?
|
DNA | 1 | 2020 | 7215 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17648 | 0.070 |
Why?
|
Kidney | 2 | 2012 | 6983 | 0.070 |
Why?
|
Clinical Competence | 1 | 2022 | 4714 | 0.070 |
Why?
|
Survival Rate | 3 | 2021 | 12746 | 0.070 |
Why?
|
Pancreatectomy | 1 | 2010 | 807 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2821 | 0.060 |
Why?
|
Vagina | 2 | 2022 | 831 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3379 | 0.060 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9355 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9613 | 0.060 |
Why?
|
Databases, Factual | 1 | 2019 | 7898 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2017 | 10358 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2012 | 905 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5726 | 0.060 |
Why?
|
Adolescent | 3 | 2023 | 86765 | 0.060 |
Why?
|
Pancreatic Neoplasms | 2 | 2011 | 5288 | 0.050 |
Why?
|
Lymphoma | 1 | 2012 | 1887 | 0.050 |
Why?
|
Fumarate Hydratase | 1 | 2022 | 52 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9551 | 0.050 |
Why?
|
Rupture | 1 | 2023 | 442 | 0.050 |
Why?
|
Groin | 1 | 2021 | 103 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6015 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39079 | 0.050 |
Why?
|
Gestational Age | 1 | 2010 | 3546 | 0.050 |
Why?
|
Cohort Studies | 5 | 2022 | 40984 | 0.050 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 8538 | 0.040 |
Why?
|
Infant, Premature | 1 | 2010 | 2064 | 0.040 |
Why?
|
Injections, Intraperitoneal | 1 | 2020 | 407 | 0.040 |
Why?
|
Atherosclerosis | 2 | 2012 | 3503 | 0.040 |
Why?
|
Diagnostic Self Evaluation | 1 | 2021 | 225 | 0.040 |
Why?
|
Male | 8 | 2023 | 354881 | 0.040 |
Why?
|
Fertility | 1 | 2023 | 773 | 0.040 |
Why?
|
Preoperative Period | 1 | 2020 | 549 | 0.040 |
Why?
|
Feedback | 1 | 2022 | 783 | 0.040 |
Why?
|
Cysteine | 1 | 2022 | 887 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 840 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2020 | 494 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 2012 | 3141 | 0.040 |
Why?
|
Education, Distance | 1 | 2021 | 253 | 0.040 |
Why?
|
North America | 1 | 2021 | 1280 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13553 | 0.040 |
Why?
|
United States | 3 | 2023 | 71442 | 0.030 |
Why?
|
Risk Factors | 3 | 2019 | 73412 | 0.030 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 239 | 0.030 |
Why?
|
Sepsis | 1 | 2010 | 2588 | 0.030 |
Why?
|
Child | 1 | 2024 | 78998 | 0.030 |
Why?
|
Digestive System Surgical Procedures | 1 | 2020 | 574 | 0.030 |
Why?
|
Lymphatic Vessels | 1 | 2019 | 354 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3404 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 1215 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2015 | 550 | 0.030 |
Why?
|
Blood Vessels | 1 | 2019 | 1114 | 0.030 |
Why?
|
Inflammation | 1 | 2012 | 10690 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4880 | 0.030 |
Why?
|
Paracentesis | 1 | 2012 | 98 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3530 | 0.020 |
Why?
|
Ascites | 1 | 2012 | 338 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2010 | 25914 | 0.020 |
Why?
|
Sex Factors | 1 | 2022 | 10455 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 35916 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 53807 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5786 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2011 | 1099 | 0.020 |
Why?
|
Hypolipidemic Agents | 1 | 2012 | 622 | 0.020 |
Why?
|
Mammography | 1 | 2019 | 2434 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5780 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3463 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3788 | 0.020 |
Why?
|
Research Design | 1 | 2022 | 6116 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2843 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8443 | 0.020 |
Why?
|
Heterozygote | 1 | 2012 | 2785 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2012 | 1060 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1892 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2012 | 1341 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12137 | 0.020 |
Why?
|
Fibrosis | 1 | 2011 | 2011 | 0.010 |
Why?
|
Postmenopause | 1 | 2012 | 2493 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 25535 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8422 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16736 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10475 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8892 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12447 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15506 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15676 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21158 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 6591 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 8496 | 0.010 |
Why?
|
Signal Transduction | 1 | 2015 | 23233 | 0.010 |
Why?
|
Infant | 1 | 2011 | 35673 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20348 | 0.000 |
Why?
|